Portal de Periódicos da CAPES

Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group

2014; Elsevier BV; Volume: 38; Issue: 7 Linguagem: Inglês

10.1016/j.leukres.2014.04.011

1873-5835

Adam Walter‐Croneck, Norbert Grząśko, Maria Soroka‐Wojtaszko, Artur Jurczyszyn, Tigran Torosian, Marcin Rymko, Adam Nowicki, Agnieszka Druzd‐Sitek, Ewa Lech‐Marańda, Elżbieta Mądro, Patrycja Zielińska, Iwona Grygoruk‐Wiśniowska, Danuta Blonska, Lidia Usnarska‐Zubkiewicz, S Potoczek, Elżbieta Iskierka, Anna Masternak, Jadwiga Hołojda, Dorota Dawidowska, Ludmila Gawron, Agnieszka Barchnicka, Magdalena Olszewska‐Szopa, Malwina Rybicka, Agnieszka Gontarska, Anna Jachalska, Piotr Rzepecki, Edyta Subocz, Piotr Boguradzki, Grzegorz Charliński, Monika Dzierżak‐Mietła, Katarzyna Wiśniewska‐Piąty, Wojciech Świstek, Agnieszka Kopacz, Beata Blajer‐Olszewska, Alina Świderska, Anna Dmoszyńska,

Protein Degradation and Inhibitors

The observational study was aimed at evaluating response, survival and toxicity of bortezomib-based, case-adjusted regimens in real-life therapy of 708 relapsed/refractory MM patients. Bortezomib was combined with anthracyclines, steroids, thalidomide, alkylators or given in monotherapy. The ORR was 67.9% for refractory and 69.9% for relapsed MM. The median PFS was 14 months and OS 57 months. Patients responding to the therapy had the probability of a 4-year OS at 67.0%. No toxicity was noted in 33.1% of patients. Severe events (grade 3/4) were reported in 35.9% of patients: neurotoxicity (16.7%), neutropenia (9.2%), thrombocytopenia (8.5%), and infections (6.5%). Bortezomib-based, case-adjusted regimens are in real-life practice effective in salvage therapy offering reliable survival with acceptable toxicity for relapsed/refractory MM patients.